For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:

https://www.mycme.com/courses/targeting-cause-emerging-therapies-menopausal-vms-10267

Summary
This enduring podcast activity explores groundbreaking advancements in the treatment of menopausal vasomotor symptoms (VMS), emphasizing non-hormonal therapies. Dr. Andrea Singer and Dr. Genevieve Neal-Perry discuss the underlying biology of menopause, particularly the role of neurokinin (NK) receptors, and introduces the science behind new therapeutic agents, as well as their clinical trial data.

This podcast was recorded and is being used with permission of the presenters.

Learning Objective
Discuss the clinical trial data for new and emerging non-hormonal therapies

This activity is accredited for CME/CE Credit
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0.25 hours of pharmacology).

For additional information about the accreditation of this program, please contact NACE at [email protected].

Summary of Individual Disclosures
Please review faculty and planner disclosures here.

Disclosure of Commercial Support
This educational activity is supported in part by an educational grant from Bayer HealthCare Pharmaceuticals Inc.

Please visit http://naceonline.com to engage in more live and on demand CME/CE content.